9 episodes

A weekly look at what's happening in the world of biotech with Labiotech.eu

Beyond Biotech - the podcast from Labiotech Labiotech

    • News

A weekly look at what's happening in the world of biotech with Labiotech.eu

    Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

    Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

    This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu.

    News: 02:30
    Endogena Therapeutics 5:10
    eureKARE 21:00
    Deep Science Ventures 33:46
    Biotech Growth Trust 47:44
    Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).
    RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for most patients. It is a leading cause of inherited blindness, with an estimated 1.5 million people worldwide presently affected.
    eureKARE, an investment company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. 
    eureKARE is developing a pan-European biotech studio network covering several areas where synthetic biology can create solutions and high market value products.
    The synthetic biology studios will focus on biomedical and other thematic applications in different European innovation hotspots. The strategy is based on identifying, selecting, and nurturing high-quality European science. 
    The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK’s innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K.
    Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration with DSV, a U.K. venture builder operating in a range of sectors including biotech, agriculture and computation. 
    According to the latest agreement, the partners will co-found startups working in up to 10 areas of oncology, such as improving the number of patients that can benefit from immuno-oncology treatments.
    The Biotech Growth Trust PLC, based in the UK, seeks capital appreciation through investment in the worldwide biotech industry. It invests in a diversified portfolio of shares and related securities in companies on a worldwide basis.
    Its portfolio is operated by U.S.-headquartered OrbiMed Capital LLC. 
    Following the strong results of the previous year, the company’s NAV (net asset value) per share total return dropped by 33.8%, compared to a 55.1% increase in 2021, and the share price total return was down 37.0%. 
    However, ​​overall, since OrbiMed’s appointment in 2005, and to the year end, The Biotech Growth Trust’s NAV has increased by 861.6% or 14.3% per annum.
    In its annual report, the portfolio manager stated the company remains confident that there are a number of potential catalysts that could lead to a recovery in the biotechnology sector this year and into the future, and their overall investment strategy remains unchanged.

    • 1 hr
    Beyond Biotech podcast 7: World Hepatitis Day

    Beyond Biotech podcast 7: World Hepatitis Day

    This week's podcast features three interviews related to hepatitis.
    Our guests are Ahmed Elsharkawy, consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham in the UK; Ziv Ben-Ari, director of the Liver Diseases Center at the Sheba Medical Center in Israel, and James McIlroy, chief executive officer at EnteroBiotix.

    World Hepatitis Day
    Taking place on July 28 every year, World Hepatitis Day unites the world under a single theme to raise awareness of the global burden of viral hepatitis with the intention of influencing real change. This year’s theme is ‘I Can’t Wait’.

    Dr Ahmed Elsharkawy is a consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham and he is also chair of hepatitis B virus special interest group which is part of the British Association for the Study of the Liver. He is a strong supporter and advocate of World Hepatitis Day. 
    Professor Ziv Ben-Ari is director of the Center for Liver Diseases and Liver Research Laboratory at the Sheba Medical Center in Israel and Professor of Medicine at Tel-Aviv University.
    She has more than 25 years of experience in evaluating candidates for liver transplantation and monitoring liver transplants including five years as a fellow in Hepatology and Liver Transplantation at the Royal Free Hospital, London.  She has chaired the Israeli Liver Research Society, chairs the Liver Committee of the National Council of Gastroenterology and is an active member of the American and European Association for the Study of the Liver. She has published more than 175 studies in leading medical journals.
    Dr James McIlroy is a qualified medical doctor and biopharmaceutical entrepreneur widely recognized as a pioneer and thought leader in the application of the microbiome to treat disease.
    He founded EnteroBiotix with the vision of building one of the world’s leading microbiome drug development companies.

    • 45 min
    Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

    Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

    On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify.

    Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza.

    Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

    Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company said propels it into next-generation cell therapy.
    The deal saw the Lausanne-based team of US venture capital firm, +ND Capital, mark its second successful exit in the European biotech market. 

    • 46 min
    Beyond Biotech podcast 5: ANeuroTech, ISA Pharmaceuticals, Life Length

    Beyond Biotech podcast 5: ANeuroTech, ISA Pharmaceuticals, Life Length

    This week’s guests are Erik Buntinx, CEO and founder of ANeuroTech; Stephen J. Matlin, CEO of Life Length; and Kees Melief, chief scientific officer at ISA Pharmaceuticals.

    • 58 min
    Beyond Biotech podcast 4: CorePath, Rensselaer, Versameb

    Beyond Biotech podcast 4: CorePath, Rensselaer, Versameb

    This week’s guests are Erik Buntinx, CEO and founder of ANeuroTech; Stephen J. Matlin, CEO of Life Length; and Kees Melief, chief scientific officer at ISA Pharmaceuticals.

    • 46 min
    Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever

    Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever

    On this week’s Labiotech.eu podcast, we have three guests.

    We had conversations with Manfred Rüdiger, CEO of Ariceum Therapeutics; Jon Hague, Unilever’s R&D VP for homecare; and Olivier Rolland, executive director at TWB.

    • 41 min

Top Podcasts In News

The New York Times
NPR
The Daily Wire
Cumulus Podcast Network | Dan Bongino
New York Times Opinion
Serial Productions

You Might Also Like

Matt Pillar
STAT
Tom Froggatt
Biotech Bros LLC.
BioCentury
Andreessen Horowitz